Tecentriq 1200 MG in 20 ML Injection + H3K27M peptide vaccine
Phase 1Active 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Newly Diagnosed H3-mutated Glioma
Conditions
Newly Diagnosed H3-mutated Glioma
Trial Timeline
Feb 15, 2023 → Nov 1, 2026
NCT ID
NCT04808245About Tecentriq 1200 MG in 20 ML Injection + H3K27M peptide vaccine
Tecentriq 1200 MG in 20 ML Injection + H3K27M peptide vaccine is a phase 1 stage product being developed by Roche for Newly Diagnosed H3-mutated Glioma. The current trial status is active. This product is registered under clinical trial identifier NCT04808245. Target conditions include Newly Diagnosed H3-mutated Glioma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04808245 | Phase 1 | Active |
Competing Products
18 competing products in Newly Diagnosed H3-mutated Glioma